Menu
Search
|

Menu

Close
X

Concordia International Corp CXRX.OQ (NASDAQ Stock Exchange Global Select Market)

0.70 USD
-0.01 (-1.41%)
As of Feb 23
chart
Previous Close 0.71
Open 0.71
Volume 5,200
3m Avg Volume 92,562
Today’s High 0.72
Today’s Low 0.70
52 Week High 2.47
52 Week Low 0.45
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
4.00 Mean rating from 1 analysts

KEY STATS

Revenue
No Data Available
FY
-
FY
-
FY
-
FY
-
EPS
No Data Available
FY
-
FY
-
FY
-
FY
-

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.62
Price to Sales (TTM)
vs sector
--
8.35
Price to Book (MRQ)
vs sector
--
5.22
Price to Cash Flow (TTM)
vs sector
--
25.88
Total Debt to Equity (MRQ)
vs sector
--
15.84
LT Debt to Equity (MRQ)
vs sector
--
12.39
Return on Investment (TTM)
vs sector
--
13.63
Return on Equity (TTM)
vs sector
--
15.39

EXECUTIVE LEADERSHIP

Jordan Kupinsky
Non-Executive Independent Chairman of the Board, Since 2016
Salary: --
Bonus: --
Wayne Kreppner
President, Chief Operating Officer, Since 2015
Salary: $600,000.00
Bonus: --
Allan Oberman
Chief Executive Officer, Director, Since 2016
Salary: $116,667.00
Bonus: --
David Price
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Graeme Duncan
President - Company's International Segment, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

277 Lakeshore Rd E Suite 302
OAKVILLE   ON   L6J 1H9

Phone: +1905.8425150

Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer; Concordia International, includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines; Orphan Drugs, includes Photofrin, which is for the treatment of certain forms of rare cancer, and Corporate cost centre, includes centralized costs incurred by the Company.

SPONSORED STORIES